



## ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ

USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process is thorough and designed to balance the need to provide athletes access to critical medication while protecting the rights of clean athletes to complete on a level playing field.

Included in this document is a checklist of items necessary for a complete TUE Application. (Please be aware that the TUE Committee may ask for additional information while evaluating TUE Applications). It is important that the TUE Application include all the documentation outlined in the checklist below. Please reference the included guidelines for details related to types of diagnoses, specific laboratory tests, and more.





## **TUE APPLICATION CHECKLIST – POST INFECTIOUS COUGH**

Complete and legible TUE Application form	
Copies of all relevant examinations and clinical notes from the original diagnosis through present	
0	The physician should rule out that the cough is not due to any of the following conditions: asthma, smoking, environmental factors, sinusitis, allergic rhinitis, viral infections, GERD, bronchitis, medication induced, COPD, or pertussis.
Copies	of all laboratory results/reports related to the diagnosis, if applicable
A state	ement from the physician explaining why the Prohibited Substance is needed. Why other treatments (with either permitted or prohibited substances/methods) failed or are not appropriated for treating the condition.  If Beta-2 agonists are being considered/utilized as a part of treatment, please ensure that the status of the medication is understood by checking Global DRO. If a prohibited Beta-2 agonist is being prescribed, the physician must provide justification explaining why a non-prohibited alternative is not appropriate. In the case of Beta-2 agonists, this should include comment on salbutamol/albuterol, formoterol, and salmeterol as these substances can be used via inhalation as long as they do not exceed their respective allowable thresholds. For more information on Beta-2 agonists, please click visit USADA's website or click here.